Text Size

Positron Emission Tomography - Computed Tomography (PET-CT) Scan as a Diagnostic Method in Unknown Primary Tumors

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Gedske Daugaard, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier:
NCT00269373
First received: December 22, 2005
Last updated: February 20, 2012
Last verified: February 2012
History of Changes
  Purpose

Is PET-CT scan better than PET or CT alone in diagnosing primary tumours in patients with unknown primary tumors? Can information obtained with PET-CT replace other clinical and radiological investigations? Is PET/CT cost-effective?


Condition Intervention
Unknown Primary Tumor
 Procedure: PET-CT

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: PET-CT Scan as a Diagnostic Method in Unknown Primary Tumors

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Rigshospitalet, Denmark:

Enrollment: 136
Study Start Date: December 2005
Study Completion Date: February 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: PET-CT
    no drugs included
Detailed Description:

Patients who fulfill the international definition of unknown primary tumors can be included, except:

  • Young men (<55 years) with growing mid-line tumors where a germ cell tumor could be expected will not be included.
  • Patients with lymph-node metastases with squamous cell carcinoma in the head and neck region will not be included.
  • Women with adenocarcinoma in lymph nodes in the axilla will not be included.
  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with unknown tumors

Criteria

Inclusion Criteria:

  • Unknown primary tumors

Exclusion Criteria:

  • Young men (<55 years) with growing mid-line tumors where a germ cell tumor could be expected will not be included.
  • Patients with lymph-node metastases with squamous cell carcinoma in the head and neck region will not be included
  • Women with adenocarcinoma in lymph nodes in the axilla will not be included
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00269373

Locations
Denmark
Rigshospitalet
Copenhagen, Denmark, 2100
Sponsors and Collaborators
Rigshospitalet, Denmark
Investigators
Principal Investigator: Gedske Daugaard Rigshospitalet, Denmark
  More Information

No publications provided

Responsible Party: Gedske Daugaard, Associate professor, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier: NCT00269373     History of Changes
Other Study ID Numbers: 01 283694
Study First Received: December 22, 2005
Last Updated: February 20, 2012
Health Authority: Denmark: Ethics Committee

Keywords provided by Rigshospitalet, Denmark:
Unknown primary tumor
PET-CT

Additional relevant MeSH terms:
Neoplasms, Unknown Primary
Neoplasm Metastasis
Neoplastic Processes
Neoplasms
Pathologic Processes

ClinicalTrials.gov processed this record on May 16, 2013